is the stopping of blood flow, an essential mechanism protecting the body from both external and internal injury.

A. Constipation: Constipation is not a commonly reported adverse effect of clopidogrel (Plavix). Clopidogrel is an antiplatelet medication that works by inhibiting platelet aggregation, and gastrointestinal effects such as constipation are not typically associated with its use.

B. Bruising: This is a correct answer. Bruising is a known adverse effect of clopidogrel. As an antiplatelet medication, clopidogrel inhibits platelet aggregation, which can increase the risk of bleeding and bruising.

C. Rash: Rash is a potential adverse effect of clopidogrel, although it is not as common as other side effects such as bruising or gastrointestinal symptoms. Patients taking clopidogrel should be monitored for signs of allergic reactions, including rash, which may indicate the need for further evaluation or discontinuation of the medication.

D. Headache: Headache is not a commonly reported adverse effect of clopidogrel. While some patients may experience headache while taking clopidogrel, it is not considered a frequent or significant side effect of the medication.

E. Diarrhea: Diarrhea is not a commonly reported adverse effect of clopidogrel. Gastrointestinal symptoms such as diarrhea are not typically associated with clopidogrel use, although some patients may experience gastrointestinal upset as a side effect of antiplatelet therapy.

A. Oprelvekin (Neumega): Oprelvekin is a recombinant human interleukin-11 (IL-11) used to stimulate the production of platelets, not red blood cells. It is primarily indicated for patients with thrombocytopenia (low platelet count) due to chemotherapy.

B. Epoetin alfa (Procrit): Epoetin alfa is a synthetic form of erythropoietin, a hormone produced by the kidneys that stimulates the production of red blood cells in the bone marrow. It is commonly used to treat anemia associated with chronic kidney disease, chemotherapy, or HIV therapy. Therefore, it is administered to increase the number of circulating red blood cells.

C. Clopidogrel (Plavix): Clopidogrel is an antiplatelet medication that inhibits platelet aggregation, thereby reducing the risk of blood clots. It does not directly stimulate the production of red blood cells.

D. Filgrastim (Neupogen): Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the production of white blood cells, particularly neutrophils, in the bone marrow. It is used to treat neutropenia (low white blood cell count) caused by chemotherapy, bone marrow transplantation, or certain diseases. It does not directly stimulate the production of red blood cells.